Intrinsic ALK-TKI Resistance Due to MetCoamplification in ALK plus NSCLC, Effectively Treated by Alectinib-crizotinib Combination

被引：0
|
作者：
Urbanska, E. M. [1 ]
Melchior, L. C. [1 ]
Sorensen, J. B. [1 ,2 ]
Santoni-Rugiu, E. [1 ,2 ]
机构：
[1] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
de novo MET-amplification; intrinsic ALK-TKI resistance; TKIs combination;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12B.12
引用
收藏
页码：S645 / S646
页数：2
相关论文
共 50 条
  • [41] A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK plus non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761).
    Gandhi, Leena
    Shaw, Alice
    Gadgeel, Shirish M.
    Riely, Gregory
    Cetnar, Jeremy
    West, Howard Jack
    Camidge, D. Ross
    Socinski, Mark A.
    Chiappori, Alberto
    Mekhail, Tarek
    Chao, Bo H.
    Borghaei, Hossein
    Gold, Kathryn A.
    Zeaiter, Ali Hassan
    Bordogna, Walter
    Balas, Bogdana
    Puig, Oscar
    Henschel, Volkmar
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naive advanced ALK plus nonsmall cell lung cancer (NSCLC)
    Zhou, C.
    Lu, Y.
    Kim, S-W.
    Baisamut, T. R.
    Zhou, J.
    Zhang, Y.
    He, J.
    Yang, J-J.
    Cheng, Y.
    Lee, S-H.
    Chang, J.
    Fang, J.
    Liu, Z.
    Bu, L.
    Qian, L.
    Archer, V. R.
    Zhou, M.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1634 - S1635
  • [43] Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC
    Mok, T. S. K.
    Shaw, A. T.
    Camidge, R. D.
    Gadgeel, S. M.
    Rosell, R.
    Dziadziuszko, R.
    Kim, D-W.
    Perol, M.
    Ou, S-H.
    Bordogna, W.
    Smoljanovic, V.
    Hilton, M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 607 - 607
  • [44] Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK plus advanced NSCLC
    Zhou, C.
    Lu, Y.
    Kim, S-W.
    Reungwetwattana, T.
    Zhou, J.
    Zhang, Y.
    He, J.
    Yang, J. J.
    Cheng, Y.
    Lee, S. H.
    Bu, L.
    Xu, T.
    Yang, L.
    Wang, C.
    Morcos, P. N.
    Mitry, E.
    Liu, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 740 - 740
  • [45] Discovery of novel targets for effective combination drug therapy in ALK plus NSCLC patient derived models of acquired resistance
    Crystal, Adam S.
    Engelman, Jeffrey A.
    Benes, Cyril H.
    Gomez-Caraballo, Maria G.
    Frias, Rosa
    Lockerman, Elizabeth
    Shaw, Alice T.
    CANCER RESEARCH, 2014, 74 (19)
  • [46] Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC
    Mazieres, J.
    Novello, S.
    De Castro, J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    Wolf, J.
    Zeaiter, A.
    Cardona, A.
    Balas, B.
    Karagiannis, T.
    Chlistalla, M.
    Smoljanovic, V.
    Oh, I.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1897 - S1897
  • [47] Circulating free DNA as a prognostic biomarker in patients with advanced ALK plus NSCLC treated with alectinib from the global phase III ALEX trial.
    Dziadziuszko, Rafal
    Peters, Solange
    Mok, Tony S. K.
    Camidge, D. Ross
    Noe, Johannes
    Nowicka, Malgorzata
    Bordogna, Walter
    Morcos, Peter N.
    Smoljanovic, Vlatka
    Tsang, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC.
    Peters, Solange
    Mok, Tony S. K.
    Gadgeel, Shirish M.
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong Ignatius
    Shaw, Alice Tsang
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Ruf, Thorsten
    Archer, Venice Rosale
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK plus NSCLC: A multicenter retrospective analysis in China
    Zou, Zihua
    Hao, Xuezhi
    Zhang, Cuiying
    Li, Haojing
    Dong, Guilan
    Peng, Yumei
    Ma, Kewei
    Guo, Ye
    Shan, Li
    Zhang, Yan
    Liang, Li
    Gu, Yangchun
    Xing, Puyuan
    Li, Junling
    THORACIC CANCER, 2022, 13 (01) : 107 - 116
  • [50] Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
    Ou, Sai-Hong Ignatius
    Azada, Michele
    Hsiang, David J.
    Herman, June M.
    Kain, Tatiana S.
    Siwak-Tapp, Christina
    Casey, Cameron
    He, Jie
    Ali, Siraj M.
    Klempner, Samuel J.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 549 - 553
12345